Innovative Bio-Platform Sea Lane offers cutting-edge fully human bio-therapeutic platform technologies, including Surrobodies and advanced antibody libraries, which can be licensed or integrated into external discovery efforts, presenting opportunities for collaborative R&D partnerships.

Strategic Acquisition The recent acquisition by I2pharma highlights interest in Sea Lane’s proprietary antibody and engineered protein technologies, opening avenues for joint development projects and technology licensing deals with biopharmaceutical companies focused on personalized cancer therapies.

Engagement in Silicon Valley Located in the heart of Silicon Valley, Sea Lane benefits from proximity to innovative biotech ecosystems, enabling potential collaborations with tech-driven biotech firms and opportunities for technological integrations using cloud and web technologies.

Emerging Market Presence With revenue under $1 million and a relatively small team, Sea Lane presents opportunities for early-stage investment partnerships, contract research services, or supply agreements to accelerate product development and commercialization efforts.

Technology Stack Leverage Utilizing advanced infrastructure such as AWS, React, and Apache, Sea Lane's technological foundation supports scalable solutions and digital collaborations, ideal for partners seeking technological innovation and integration capabilities.